cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.28937255.v1
title: Effects of green tea supplementation on obesity indices and adipokines in adults: a grade-assessed systematic review and dose-response meta-analysis of randomised controlled trials

description: In this systematic review and meta-analysis, the impact of green tea supplementation on measurement/indices of adiposity was investigated. Using predefined keywords, online databases (PubMed, Scopus, Web of Science Core Collection, and Google Scholar) were searched for relevant studies, published from inception up to February 2024. Data were extracted and registered. Subgroup analyses and the investigation of linear and non-linear associations were carried out. Green tea supplementation reduced BW (WMD: −0.74 kg; 95% CI: −0.97, −0.51), BMI (WMD: −0.29 kg/m<sup>2</sup>; 95% CI: −0.38, −0.19), WC (WMD: −1.04 cm; 95% CI: −1.55, −0.53), BFP (WMD: −0.65%; 95% CI: −1.03, −0.27), and leptin (WMD: −0.92 ng/ml; 95% CI: −1.71, −0.14), but did not change adiponectin levels (WMD: 0.20 µg/ml; 95% CI: −0.17, 0.57). Supplementation with green tea seems to be effective in reducing excess adiposity.
DOI: 10.6084/m9.figshare.28955305
title: Whole-body hyperthermia as part of a multimodal treatment for patients with post-covid syndrome – a case series

description: Post-Covid syndrome (PCS) has been an ongoing challenge since the COVID-19 pandemic. Relatively little is known about the effect of whole-body hyperthermia (WBH) in the treatment of PCS. We retrospectively analyzed the data of patients with PCS who were treated as inpatients with a multimodal integrative therapy approach including WBH. The primary outcome comprised changes in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) between T0 (at hospital admission) and T2 (four weeks after discharge), secondary outcomes were changes in Fatigue Impact Scale (FIS-D), Multidimensional Dyspnea Profile (MDP) and Covid-Associated Symptoms (CAS) between T0–T1 (at discharge) and T0–T2. FACIT-F yielded a significant increase (<i>p</i> &lt; 0.001) between T0 (19.1 ± 8.4) and T2 (29.9 ± 13.0) (primary outcome), indicating an improved health status. While FIS-D and CAS scores improved significantly between T0 and T2, dyspnea parameters improved only between T0 and T1. 63% of respondents identified WBH as an effective treatment. Study results provide preliminary evidence for potentially positive effects of WBH in the setting of this study, in which it is embedded in a multimodal therapy approach. The results should be substantiated by future RCTs to identify specific effects of individual therapy components.
DOI: 10.6084/m9.figshare.28955305.v1
title: Whole-body hyperthermia as part of a multimodal treatment for patients with post-covid syndrome – a case series

description: Post-Covid syndrome (PCS) has been an ongoing challenge since the COVID-19 pandemic. Relatively little is known about the effect of whole-body hyperthermia (WBH) in the treatment of PCS. We retrospectively analyzed the data of patients with PCS who were treated as inpatients with a multimodal integrative therapy approach including WBH. The primary outcome comprised changes in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) between T0 (at hospital admission) and T2 (four weeks after discharge), secondary outcomes were changes in Fatigue Impact Scale (FIS-D), Multidimensional Dyspnea Profile (MDP) and Covid-Associated Symptoms (CAS) between T0–T1 (at discharge) and T0–T2. FACIT-F yielded a significant increase (<i>p</i> &lt; 0.001) between T0 (19.1 ± 8.4) and T2 (29.9 ± 13.0) (primary outcome), indicating an improved health status. While FIS-D and CAS scores improved significantly between T0 and T2, dyspnea parameters improved only between T0 and T1. 63% of respondents identified WBH as an effective treatment. Study results provide preliminary evidence for potentially positive effects of WBH in the setting of this study, in which it is embedded in a multimodal therapy approach. The results should be substantiated by future RCTs to identify specific effects of individual therapy components.
DOI: 10.6084/m9.figshare.28415025
title: Efficacy of focused ultrasound ablation surgery in patients with adenomyosis and coexisting pelvic adhesions

description: The objective of this study was to assess the efficacy of focused ultrasound ablation surgery (FUAS) in treating patients with adenomyosis and coexisting pelvic adhesions. A total of 396 patients diagnosed with adenomyosis and who underwent FUAS between January 2014 and December 2022 were enrolled. Pelvic adhesions were evaluated using magnetic resonance imaging (MRI), and the patients were categorized into either adhesive group or non-adhesive group. The aim was to investigate the comparative efficacy between the two groups. Among the 396 patients, pelvic adhesions were detected in 123 (31.06%) women. Compared to the non-adhesive group, patients in the adhesive group exhibited a higher preoperative dysmenorrhea score (7 <i>vs.</i> 6, <i>p</i>  &lt; 0.001), a lower short-term clinical success rate (74.80% <i>vs.</i> 84.62%, <i>p</i> = 0.025), and a higher long-term cumulative recurrence rate (log-rank <i>p</i> = 0.009). The adhesive group exhibited a high incidence of anal discomfort during the procedure compared to the non-adhesive group (18.70% <i>vs.</i> 7.69%, <i>p</i> = 0.002). Additionally, patients with severe adhesion demonstrated a lower ratio of non-perfused volume ratio (NPVR) (38.81% <i>vs.</i> 46.58%, <i>p</i> = 0.009). Multivariate binary logistic regression analysis revealed that pelvic adhesion independently increased the risk of dysmenorrhea (OR = 4.730, 95%CI: 2.026–11.044, <i>p</i> &lt; 0.001), while severe pelvic adhesion was identified as an independent risk factor for NPVR (OR = 2.226, 95%CI: 1.181–4.196, <i>p</i> = 0.013). The preoperative assessment of pelvic adhesions plays a crucial role in predicting intraoperative adverse events of FUAS in patients with adenomyosis, as well as determining both short-term and long-term efficacy, thereby providing valuable guidance for the development of comprehensive treatment.
DOI: 10.6084/m9.figshare.28415025.v1
title: Efficacy of focused ultrasound ablation surgery in patients with adenomyosis and coexisting pelvic adhesions

description: The objective of this study was to assess the efficacy of focused ultrasound ablation surgery (FUAS) in treating patients with adenomyosis and coexisting pelvic adhesions. A total of 396 patients diagnosed with adenomyosis and who underwent FUAS between January 2014 and December 2022 were enrolled. Pelvic adhesions were evaluated using magnetic resonance imaging (MRI), and the patients were categorized into either adhesive group or non-adhesive group. The aim was to investigate the comparative efficacy between the two groups. Among the 396 patients, pelvic adhesions were detected in 123 (31.06%) women. Compared to the non-adhesive group, patients in the adhesive group exhibited a higher preoperative dysmenorrhea score (7 <i>vs.</i> 6, <i>p</i>  &lt; 0.001), a lower short-term clinical success rate (74.80% <i>vs.</i> 84.62%, <i>p</i> = 0.025), and a higher long-term cumulative recurrence rate (log-rank <i>p</i> = 0.009). The adhesive group exhibited a high incidence of anal discomfort during the procedure compared to the non-adhesive group (18.70% <i>vs.</i> 7.69%, <i>p</i> = 0.002). Additionally, patients with severe adhesion demonstrated a lower ratio of non-perfused volume ratio (NPVR) (38.81% <i>vs.</i> 46.58%, <i>p</i> = 0.009). Multivariate binary logistic regression analysis revealed that pelvic adhesion independently increased the risk of dysmenorrhea (OR = 4.730, 95%CI: 2.026–11.044, <i>p</i> &lt; 0.001), while severe pelvic adhesion was identified as an independent risk factor for NPVR (OR = 2.226, 95%CI: 1.181–4.196, <i>p</i> = 0.013). The preoperative assessment of pelvic adhesions plays a crucial role in predicting intraoperative adverse events of FUAS in patients with adenomyosis, as well as determining both short-term and long-term efficacy, thereby providing valuable guidance for the development of comprehensive treatment.
DOI: 10.6084/m9.figshare.28251051
title: Addition of PARP1-inhibition enhances chemoradiotherapy and thermoradiotherapy when treating cervical cancer in an <i>in vivo</i> mouse model

description: <b>Background:</b> Efficacy of current treatment options for cervical cancer require improvement. Previous <i>in vitro</i> studies have shown the enhancing effects of the addition of PARP1-inhibitors to chemoradiotherapy and thermoradiotherapy. The aim of our present study was to test efficacy of different combinations of treatment modalities radiotherapy, cisplatin, hyperthermia and PARP1-inhibitors using <i>in vitro</i> tumor models, <i>ex vivo</i> treated patient samples and <i>in vivo</i> tumor models. <b>Materials and Methods:</b><i>In vitro</i> clonogenic survival curves (0–6 Gy) show that PARP1<i>-i</i> (4–5 M Olaparib) enhances both chemoradiotherapy (0.3–0.5 µM cisplatin) and thermoradiotherapy (42 °C for 1 h) in SiHa, CaSki and HeLa cells. A cervical cancer mouse model and freshly obtained in-house developed patient-derived organoids were used to examine the effects of different treatment combinations. For the <i>in vivo</i> study, human cervical cancer (SiHa) cells were injected in the right hind leg of athymic nude mice. <i>In vivo</i> mouse experiments show that PARP1<i>-i</i> enhances thermoradiotherapy or chemoradiotherapy by reduction of tumor volumes. Five cycles of treatment were applied with the following doses per cycle: irradiation 3 Gy, hyperthermia 1 h at 42 °C, cisplatin at 2 mg/kg, and twice PARP1<i>-i</i> at 50 mg/kg. <b>Results:</b> Quadruple treatment, combining radiotherapy, hyperthermia, cisplatin and PARP1<i>-i</i>, was very effective but also lead to severe side effects causing severe weight loss and death. In contrast, thermoradiotherapy or chemoradiotherapy with addition of PARP1-<i>i,</i> were effective without serious side effects. <b>Conclusion:</b> The triple combinations are promising options for potentially more effective treatment of locally advanced cervical cancer without more toxicity.
DOI: 10.6084/m9.figshare.28251051.v1
title: Addition of PARP1-inhibition enhances chemoradiotherapy and thermoradiotherapy when treating cervical cancer in an <i>in vivo</i> mouse model

description: <b>Background:</b> Efficacy of current treatment options for cervical cancer require improvement. Previous <i>in vitro</i> studies have shown the enhancing effects of the addition of PARP1-inhibitors to chemoradiotherapy and thermoradiotherapy. The aim of our present study was to test efficacy of different combinations of treatment modalities radiotherapy, cisplatin, hyperthermia and PARP1-inhibitors using <i>in vitro</i> tumor models, <i>ex vivo</i> treated patient samples and <i>in vivo</i> tumor models. <b>Materials and Methods:</b><i>In vitro</i> clonogenic survival curves (0–6 Gy) show that PARP1<i>-i</i> (4–5 M Olaparib) enhances both chemoradiotherapy (0.3–0.5 µM cisplatin) and thermoradiotherapy (42 °C for 1 h) in SiHa, CaSki and HeLa cells. A cervical cancer mouse model and freshly obtained in-house developed patient-derived organoids were used to examine the effects of different treatment combinations. For the <i>in vivo</i> study, human cervical cancer (SiHa) cells were injected in the right hind leg of athymic nude mice. <i>In vivo</i> mouse experiments show that PARP1<i>-i</i> enhances thermoradiotherapy or chemoradiotherapy by reduction of tumor volumes. Five cycles of treatment were applied with the following doses per cycle: irradiation 3 Gy, hyperthermia 1 h at 42 °C, cisplatin at 2 mg/kg, and twice PARP1<i>-i</i> at 50 mg/kg. <b>Results:</b> Quadruple treatment, combining radiotherapy, hyperthermia, cisplatin and PARP1<i>-i</i>, was very effective but also lead to severe side effects causing severe weight loss and death. In contrast, thermoradiotherapy or chemoradiotherapy with addition of PARP1-<i>i,</i> were effective without serious side effects. <b>Conclusion:</b> The triple combinations are promising options for potentially more effective treatment of locally advanced cervical cancer without more toxicity.
DOI: 10.6084/m9.figshare.30949266
title: Areolar sebaceous hyperplasia: case report and literature review

description: Areolar sebaceous hyperplasia (ASH), also known as Montgomery hyperplasia, is an uncommon benign neoplasm. Despite nearly 40 years since the first case was described, this condition remains rare, with only 20 reported cases. We present a case of ASH in a 44-year-old female and review the existing literature.
DOI: 10.6084/m9.figshare.30949266.v1
title: Areolar sebaceous hyperplasia: case report and literature review

description: Areolar sebaceous hyperplasia (ASH), also known as Montgomery hyperplasia, is an uncommon benign neoplasm. Despite nearly 40 years since the first case was described, this condition remains rare, with only 20 reported cases. We present a case of ASH in a 44-year-old female and review the existing literature.
DOI: 10.6084/m9.figshare.28652643
title: Clinical effects of acute lamotrigine overdose (ATOM-10)

description: Lamotrigine overdose is not typically associated with severe toxicity. However, both severe toxicity and serotonin toxicity is occasionally reported following large ingestions. We aimed to investigate the clinical effects of lamotrigine overdose. This was a prospective observational study from July 2020-March 2024. Patients &gt;14 years-old with acute lamotrigine overdose (≥2 g ingestion) were recruited from the Australian Toxicology Monitoring study or identified from three toxicology units. Data extracted included clinical features, lamotrigine concentrations, management, and outcomes. Fifty-four patients were included, median age 29 years (IQR: 21–42 years), 37 (69%) were female. The median ingested dose was 4.8 g (IQR: 3.2-6.3 g) and 41 patients (76%) co-ingested other substances. The median maximum lamotrigine concentration was 18.5 mg/L (IQR: 12.4–25.0 mg/L) at a median time of 4.3 h (IQR: 3.2–10.8 h) post-ingestion. Clinical effects and their management included sedation in 44 (81%) with 29 patients (54%) endotracheally intubated, tachycardia in 39 (72%), hypotension in 21 (39%) with 15 (28%) receiving inotropes, and seizures in 11 (20%). Serotonin toxicity occurred in 23 (43%) patients with four having severe toxicity characterised by temperature &gt;38.5 °C and/or rigidity treated with muscle paralysis. Higher peak lamotrigine concentrations were correlated with severe outcomes such as endotracheal intubation for coma (<i>P </i>&lt;0.0001), patients with hypotension receiving inotropes (<i>P</i> = 0.0269) and patients developing seizures (<i>P</i> = 0.0002). Patients who co-ingested another serotonin agent (some in therapeutic doses) had a higher incidence of developing serotonin toxicity (22/33 [67%]) versus those who had not (1/21 [5%]); <i>P</i> &lt;0.0001). Severe toxicity was associated with higher peak lamotrigine concentrations. Serotonin toxicity was common in those who were exposed to another serotonergic agent. Coma, seizures and hypotension following lamotrigine overdose appeared to be concentration dependent. Serotonin toxicity occurred in those who co-ingested another serotonergic agent and was unrelated to lamotrigine concentration.
DOI: 10.6084/m9.figshare.28652643.v1
title: Clinical effects of acute lamotrigine overdose (ATOM-10)

description: Lamotrigine overdose is not typically associated with severe toxicity. However, both severe toxicity and serotonin toxicity is occasionally reported following large ingestions. We aimed to investigate the clinical effects of lamotrigine overdose. This was a prospective observational study from July 2020-March 2024. Patients &gt;14 years-old with acute lamotrigine overdose (≥2 g ingestion) were recruited from the Australian Toxicology Monitoring study or identified from three toxicology units. Data extracted included clinical features, lamotrigine concentrations, management, and outcomes. Fifty-four patients were included, median age 29 years (IQR: 21–42 years), 37 (69%) were female. The median ingested dose was 4.8 g (IQR: 3.2-6.3 g) and 41 patients (76%) co-ingested other substances. The median maximum lamotrigine concentration was 18.5 mg/L (IQR: 12.4–25.0 mg/L) at a median time of 4.3 h (IQR: 3.2–10.8 h) post-ingestion. Clinical effects and their management included sedation in 44 (81%) with 29 patients (54%) endotracheally intubated, tachycardia in 39 (72%), hypotension in 21 (39%) with 15 (28%) receiving inotropes, and seizures in 11 (20%). Serotonin toxicity occurred in 23 (43%) patients with four having severe toxicity characterised by temperature &gt;38.5 °C and/or rigidity treated with muscle paralysis. Higher peak lamotrigine concentrations were correlated with severe outcomes such as endotracheal intubation for coma (<i>P </i>&lt;0.0001), patients with hypotension receiving inotropes (<i>P</i> = 0.0269) and patients developing seizures (<i>P</i> = 0.0002). Patients who co-ingested another serotonin agent (some in therapeutic doses) had a higher incidence of developing serotonin toxicity (22/33 [67%]) versus those who had not (1/21 [5%]); <i>P</i> &lt;0.0001). Severe toxicity was associated with higher peak lamotrigine concentrations. Serotonin toxicity was common in those who were exposed to another serotonergic agent. Coma, seizures and hypotension following lamotrigine overdose appeared to be concentration dependent. Serotonin toxicity occurred in those who co-ingested another serotonergic agent and was unrelated to lamotrigine concentration.
DOI: 10.15468/dl.546qua
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{"type":"and","predicates":[{"type":"within","geometry":"POLYGON ((100.261 1.530182, 100.190712 1.524614, 100.122156 1.508047, 100.057021 1.48089, 99.99691 1.443811, 99.943305 1.397723, 99.897526 1.343763, 99.860699 1.283259, 99.83373 1.217701, 99.817284 1.148704, 99.811763 1.077967, 99.81730399999999 1.007231, 99.833769 0.938239, 99.86075200000001 0.872688, 99.897589 0.8121930000000001, 99.943372 0.758243, 99.996973 0.712166, 100.057074 0.675095, 100.122195 0.647945, 100.190733 0.631383, 100.261 0.625816, 100.331267 0.631383, 100.399805 0.647945, 100.464926 0.675095, 100.525027 0.712166, 100.578628 0.758243, 100.624411 0.8121930000000001, 100.661248 0.872688, 100.688231 0.938239, 100.704696 1.007231, 100.710237 1.077967, 100.704716 1.148704, 100.68827 1.217701, 100.661301 1.283259, 100.624474 1.343763, 100.578695 1.397723, 100.52509 1.443811, 100.464979 1.48089, 100.399844 1.508047, 100.331288 1.524614, 100.261 1.530182))"},{"type":"equals","key":"CLASS_KEY","value":"212","matchCase":false},{"type":"greaterThanOrEquals","key":"YEAR","value":"2015","matchCase":false},{"type":"not","predicate":{"type":"in","key":"BASIS_OF_RECORD","values":["MATERIAL_CITATION","MATERIAL_SAMPLE","PRESERVED_SPECIMEN"],"matchCase":false}},{"type":"lessThanOrEquals","key":"COORDINATE_UNCERTAINTY_IN_METERS","value":"10000","matchCase":false},{"type":"equals","key":"LICENSE","value":"CC BY 4.0","matchCase":false}]}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002291-260120142942310/datasets/export for details.
DOI: 10.6084/m9.figshare.30490062
title: Mesenchymal stromal cell-derived extracellular vesicles as a next-generation therapy for ARDS: mechanisms, advances, and future directions

description: Acute respiratory distress syndrome (ARDS) is a life-threatening syndrome characterized by diffuse alveolar damage, severe hypoxemia, and dysregulated inflammation. Despite improvements in lung-protective ventilation and supportive care, mortality remains high, highlighting the need for therapies targeting core mechanisms of injury and repair. Mesenchymal stromal cells (MSCs) have demonstrated therapeutic potential largely via paracrine mechanisms, with extracellular vesicles (EVs) emerging as a cell-free alternative that retains key MSC benefits while overcoming limitations related to cell viability, engraftment, and scalability. This review synthesizes current evidence on MSC-derived EVs (MSC-EVs) in ARDS, encompassing mechanisms of action, preclinical efficacy, delivery strategies, and translational challenges. Studies published from 2015 to 2025 were retrieved from PubMed, Web of Science, and ClinicalTrials.gov. Emphasis is placed on immunomodulatory effects, restoration of alveolar – capillary barrier integrity, and transfer of functional proteins, mRNAs, and microRNAs. MSC-EVs represent a promising, disease-modifying therapy with potential to reduce ventilation duration, extracorporeal support, and overall healthcare burden. Key challenges remain, including standardized manufacturing, validated potency assays, and identification of patient selection biomarkers. Integration of bioengineering innovations, GMP-compliant production pipelines, and stratified clinical trial designs will be critical to accelerate translation and enable definitive evaluation in late-phase studies.
DOI: 10.6084/m9.figshare.30490062.v1
title: Mesenchymal stromal cell-derived extracellular vesicles as a next-generation therapy for ards: mechanisms, advances, and future directions

description: Acute respiratory distress syndrome (ARDS) is a life-threatening syndrome characterized by diffuse alveolar damage, severe hypoxemia, and dysregulated inflammation. Despite improvements in lung-protective ventilation and supportive care, mortality remains high, highlighting the need for therapies targeting core mechanisms of injury and repair. Mesenchymal stromal cells (MSCs) have demonstrated therapeutic potential largely via paracrine mechanisms, with extracellular vesicles (EVs) emerging as a cell-free alternative that retains key MSC benefits while overcoming limitations related to cell viability, engraftment, and scalability. This review synthesizes current evidence on MSC-derived EVs (MSC-EVs) in ARDS, encompassing mechanisms of action, preclinical efficacy, delivery strategies, and translational challenges. Studies published from 2015 to 2025 were retrieved from PubMed, Web of Science, and ClinicalTrials.gov. Emphasis is placed on immunomodulatory effects, restoration of alveolar – capillary barrier integrity, and transfer of functional proteins, mRNAs, and microRNAs. MSC-EVs represent a promising, disease-modifying therapy with potential to reduce ventilation duration, extracorporeal support, and overall healthcare burden. Key challenges remain, including standardized manufacturing, validated potency assays, and identification of patient selection biomarkers. Integration of bioengineering innovations, GMP-compliant production pipelines, and stratified clinical trial designs will be critical to accelerate translation and enable definitive evaluation in late-phase studies.